Mesothelioma Brain Metastasis

Mesothelioma brain metastasis is the spread of malignant mesothelioma (MM) — most commonly the pleural or pericardial form — to the central nervous system (CNS), an event documented in approximately 2.7% of mesothelioma cases pooled across seven autopsy series of 655 patients. CNS involvement is historically a late event, frequently masked by progressive thoracic disease and short overall survival, and prior to 2026 the genetic and immunohistochemical profile of any mesothelioma brain metastasis had never been systematically published. In May 2026, a Stanford University team led by Paul M. Harary reported the first dedicated genetic and immunohistochemical profiling of malignant mesothelioma with brain metastasis — two cases (one pericardial, one pleural) sequenced with hybrid-capture next-generation sequencing, with somatic alterations identified in RAD51C (Case 1), NF2 splice-site, and TP53 frameshift (Case 2). Treatment decisions hinge on whole-brain radiotherapy (WBRT) versus stereotactic radiosurgery (SRS), dose-by-size relationships established by Radiation Therapy Oncology Group (RTOG) protocol 90-05, and the cognitive-preservation benefit of hippocampal avoidance demonstrated by NRG Oncology CC001.

Mesothelioma Brain Metastasis
Epidemiology, Genetics, and Treatment
Pooled CNS Prevalence (Autopsy)	2.7% (18 of 655)
Anchor Study	Harary 2026, Stanford
Genetic Alterations Reported	RAD51C, NF2, TP53
Histologic Dedifferentiation in BM	17% (6 of 35 paired)
SRS MTD (≤20 mm)	24 Gy single fraction
SRS MTD (21–30 mm)	18 Gy single fraction
SRS MTD (31–40 mm)	15 Gy single fraction
HA-WBRT Cognitive Failure HR (vs WBRT)	0.74 (NRG CC001)
BAP1+MTAP+Merlin IHC Panel Sensitivity	90%
Peritoneal MM CNS Spread (Pooled)	0 cases
Post-BM Survival, Harary Case 2	6 months (SRS)

Executive Summary

Mesothelioma brain metastasis is uncommon but underdiagnosed. The pooled autopsy prevalence is approximately 2.7% across 655 patients in seven series compiled by Miller et al. in 2014, but the imaging-based clinical incidence is likely lower because most patients die of advanced thoracic or peritoneal disease before CNS dissemination becomes evident. In May 2026, Harary et al. of Stanford University published the first dedicated genetic and immunohistochemical profiling of MM with brain metastasis: a 20-to-25-year-old male with pericardial MM, 14 bilateral brain lesions, and a RAD51C missense variant of uncertain significance (c.492 T>G, p.F164L; Case 1) and an 85-to-90-year-old male with pleural MM, a hemorrhagic frontotemporal lesion, an NF2 splice-site mutation (c.1731_1737del+7; variant allele fraction, or VAF, 23%) and a TP53 frameshift mutation (c.295_296del; VAF 27%; Case 2). The TP53 frameshift is unusual for mesothelioma and the authors hypothesize it may be associated with rapid disease progression. Whole-brain radiotherapy (WBRT) delivered as 30 Gy in 10 fractions (six of them with hippocampal avoidance) was used for the 14-lesion Case 1; stereotactic radiosurgery (SRS) at 22 Gy in a single fraction was used for the larger frontotemporal lesion in Case 2 with 16% volume reduction at three months on follow-up imaging. Brain biopsy of any mesothelioma patient with new neurological symptoms requires a four-step immunohistochemistry workup — exclude glioma, exclude carcinoma, confirm mesothelial origin, confirm malignancy — anchored by the BAP1 + MTAP + Merlin three-marker panel validated at 90% sensitivity and 100% specificity by Chapel et al. (2022) in 84 pleural mesothelioma cases. Hybrid-capture next-generation sequencing covering BAP1, CDKN2A/MTAP, NF2, and TP53 detects a pathogenic alteration in 95% of pleural MMs; combined with immunohistochemistry the diagnostic yield reaches 99%.

At a Glance

• Mesothelioma brain metastasis is rare: pooled autopsy prevalence of 2.7% across 655 patients in seven studies (Miller 2014).
• First genetic profiling of mesothelioma with brain metastasis was published by Harary et al. at Stanford in May 2026 (Cancer Reports, IRB #3910); two cases identified mutations in RAD51C, NF2, and TP53.
• Histologic dedifferentiation occurs in 17% (6 of 35) of cases with mesothelioma histology assessed at both primary and central nervous system sites — meaning the brain biopsy may not look like the primary tumor.
• Pericardial mesothelioma — Case 1 in Harary 2026 — accounts for less than 1% of all mesotheliomas, making this CNS-involved pericardial case exceptionally rare.
• The TP53 frameshift identified in Case 2 (c.295_296del) is unusual for mesothelioma; only 14% of pleural mesotheliomas in the Chapel 2022 cohort carried a TP53 point mutation or subgenic deletion with probable biallelic inactivation.
• The BAP1 + MTAP + Merlin three-marker immunohistochemistry panel is 90% sensitive and 100% specific for pleural mesothelioma versus reactive mesothelial proliferations.
• Whole-brain radiotherapy at 30 Gy in 10 fractions is a standard palliative regimen; hippocampal-avoidance WBRT plus memantine significantly preserves cognitive function compared with standard WBRT (adjusted hazard ratio 0.74; NRG Oncology CC001).
• Stereotactic radiosurgery maximum tolerated doses established by RTOG 90-05 are 24 Gy for tumors ≤20 mm, 18 Gy for 21–30 mm, and 15 Gy for 31–40 mm.
• Nivolumab plus ipilimumab (CheckMate-743) is the standard first-line systemic regimen for unresectable pleural mesothelioma, extending median overall survival to 18.1 months versus 14.1 months with platinum-pemetrexed chemotherapy.
• Zero cases of primary peritoneal mesothelioma metastasizing to the central nervous system were identified in the pooled autopsy series or in 97 reviewed clinical cases.

Key Facts

The numeric values below consolidate the epidemiology, genetics, immunohistochemistry, and radiation-dose framework for mesothelioma brain metastasis into a single reference table. Each row pairs a statistic with its primary peer-reviewed source so that clinicians, patients, and families can cross-check claims made elsewhere on this page against the originating publication. Values reflect the 2026 evidence base, anchored by the Harary et al. 2026 Stanford case series, the Chapel et al. 2022 immunohistochemistry-plus-next-generation-sequencing validation study, the Miller et al. 2014 pooled autopsy analysis, and the Brown et al. 2020 NRG Oncology CC001 hippocampal-avoidance Phase III trial.

Metric	Value	Source / Notes
Pooled CNS prevalence in mesothelioma (autopsy series)	2.7% (18 of 655)	Miller et al. 2014 (PMID 25079105)
Histologic subtype distribution in CNS-metastatic mesothelioma	Sarcomatoid 31, biphasic 14, epithelioid 14 (of 59 specified)	Miller et al. 2014 (PMID 25079105)
Histologic dedifferentiation between primary and CNS sites	17% (6 of 35 paired cases)	Miller et al. 2014 (PMID 25079105)
Peritoneal mesothelioma with CNS metastasis	0 cases (pooled autopsy + 97 clinical)	Miller et al. 2014 (PMID 25079105)
First genetic profiling of mesothelioma brain metastasis	Harary 2026 (2 cases; Stanford IRB #3910)	Harary et al. 2026 (PMID 42101078)
BAP1 alterations in pleural mesothelioma	56% (47 of 84)	Chapel et al. 2022 (PMID 35459788)
CDKN2A alterations in pleural mesothelioma	69% (58 of 84)	Chapel et al. 2022 (PMID 35459788)
NF2 alterations in pleural mesothelioma	68% (57 of 84)	Chapel et al. 2022 (PMID 35459788)
TP53 alterations in pleural mesothelioma (any)	27% (23 of 84)	Chapel et al. 2022 (PMID 35459788)
BAP1 immunohistochemistry sensitivity / specificity	54% / 100%	Chapel et al. 2022 (PMID 35459788)
MTAP immunohistochemistry sensitivity / specificity	46% / 100%	Chapel et al. 2022 (PMID 35459788)
Merlin (NF2 product) immunohistochemistry sensitivity / specificity	52% / 100%	Chapel et al. 2022 (PMID 35459788)
BAP1 + MTAP + Merlin three-marker panel sensitivity	90% (at 100% specificity)	Chapel et al. 2022 (PMID 35459788)
Next-generation sequencing pathogenic-alteration detection rate	95% (combined with IHC: 99%)	Chapel et al. 2022 (PMID 35459788)
SRS maximum tolerated dose, tumors ≤20 mm	24 Gy single fraction	Shaw et al. 2000, RTOG 90-05 (PMID 10802351)
SRS maximum tolerated dose, tumors 21–30 mm	18 Gy single fraction	Shaw et al. 2000, RTOG 90-05 (PMID 10802351)
SRS maximum tolerated dose, tumors 31–40 mm	15 Gy single fraction	Shaw et al. 2000, RTOG 90-05 (PMID 10802351)
Hippocampal-avoidance WBRT cognitive failure (adjusted HR vs WBRT)	0.74 (95% CI 0.58–0.95; p=0.02)	Brown et al. 2020, NRG CC001 (PMID 32058845)
NRG CC001 trial enrollment	518 patients, randomized Phase III	Brown et al. 2020 (PMID 32058845)
First-line nivolumab + ipilimumab median OS in unresectable MPM	18.1 months (vs 14.1 chemo)	Baas et al. 2021, CheckMate-743 (PMID 33485464)
First somatic BAP1 mutation prevalence in MPM (historic landmark)	23% (of 53 tumors, Bott 2011)	Bott et al. 2011 (PMID 21642991)
Pericardial mesothelioma fraction of all mesotheliomas	<1%	Schaefer et al. 2023 (PMID 37295554)

What Is Mesothelioma Brain Metastasis and Why Is It Rare?

Malignant mesothelioma is a cancer of the mesothelial cells lining the pleura, peritoneum, pericardium, and tunica vaginalis. The thoracic cavity is the most common site of involvement, with pleural mesothelioma accounting for the large majority of cases, peritoneal disease the second most common, and pericardial and testicular forms exceptionally rare. The cancer typically progresses locally and through regional lymphatics, with distant hematogenous dissemination — including to the central nervous system — generally considered a late-stage event.

The most rigorous epidemiologic estimate of CNS involvement comes from the pooled autopsy analysis published by Miller and colleagues at the National Cancer Institute and the NIH Clinical Center in 2014. Their systematic review identified seven autopsy studies (Adams 1986, Finn 2012, Hartman 1996, Hulks 1989, Huncharek 1987, Schlienger 1969, and Whitwell 1971) totaling 655 mesothelioma patients with complete pathologic CNS evaluation. Eighteen patients (2.7% of the pool) had CNS metastases identified at autopsy, with individual study rates ranging from 0% to 3.8%. The investigators also reviewed 97 clinically identified mesothelioma plus brain metastasis (BM) cases in the published literature for the discussion section. Notably, zero cases of primary peritoneal mesothelioma metastasizing to the CNS were identified in either the pooled autopsy series or the 97 reviewed clinical cases — a striking organ-specific pattern that distinguishes peritoneal from pleural disease.

Several factors explain the apparent rarity of brain metastases in mesothelioma. The first is the natural history of the disease: mesothelioma typically presents at advanced thoracic or peritoneal stage with median overall survival of approximately 10 to 18 months depending on first-line treatment regimen, meaning many patients die of intrathoracic or intra-abdominal disease before hematogenous CNS seeding becomes clinically evident. The second is underdiagnosis: brain imaging is not routinely included in mesothelioma staging or surveillance, so CNS lesions are typically discovered only after neurological symptoms develop. Miller et al. concluded that "Clinicians should consider and identify CNS involvement in patients with new or evolving neurologic symptoms because early identification may allow for palliative intervention." The third is histologic shift: among 35 paired primary-and-CNS cases in Miller's review, six (17%) showed dedifferentiation at the brain metastasis site, with two becoming less differentiated and four undergoing sarcomatoid transformation — a pattern that complicates pathologic recognition because the brain biopsy may not resemble the original tumor on routine immunohistochemistry.

What Did the Stanford 2026 Study Find?

Harary, Hori, Jain, Kattaa, Gephart, Gensheimer, Soltys, Park, and Chang from the Stanford University School of Medicine Departments of Neurosurgery and Radiation Oncology published the first dedicated genetic and immunohistochemical profiling of mesothelioma with brain metastasis in Cancer Reports (Hoboken) in May 2026 (PMID 42101078; PMC13154776; DOI 10.1002/cnr2.70571). The two cases were reviewed under Stanford Institutional Review Board protocol #3910, with hybrid-capture next-generation sequencing performed on formalin-fixed paraffin-embedded tumor tissue.

Case 1 — Pericardial Mesothelioma With RAD51C Variant

Case 1 was a 20-to-25-year-old male who presented with left arm shaking, with brain magnetic resonance imaging at the time of presentation revealing 14 total brain lesions, 85.7% of which had vasogenic edema. Subsequent workup identified a pericardial primary tumor with epithelioid mesothelioma histology. The patient had no documented asbestos exposure. Family history was notable for a maternal aunt with breast cancer at age 33 and acute myeloid leukemia at age 35.

Immunohistochemistry on the tumor showed mesothelial lineage markers — WT1, CK5/6, D2-40, and calretinin positive — with carcinoma markers BerEP4, P40, and claudin-4 negative; BAP1 expression was retained. Hybrid-capture next-generation sequencing identified a RAD51C missense mutation, c.492 T>G (p.F164L) at chromosome 17 (chr17:g.58696746), classified as a variant of uncertain significance (VUS) under the American College of Medical Genetics 2015 framework. The variant allele fraction is reported as not available in the public PMC text. Importantly, no paired germline testing was performed, leaving open whether the RAD51C variant is somatic or hereditary in a patient whose young age, asbestos-naive status, and family history would have justified germline analysis.

For management of the 14 brain lesions, the patient received whole-brain radiotherapy at 30 Gy delivered in 10 fractions, including six fractions with hippocampal avoidance. Postoperatively he received nivolumab plus ipilimumab; he later received gemcitabine at 1000 mg/m². Supportive care included dexamethasone and levetiracetam. Documented toxicities included tachycardia, voice changes, taste loss, cardiomyopathy with a left ventricular ejection fraction of 50%, and respiratory failure. Overall survival was 21.25 months from initial mesothelioma diagnosis, with brain metastasis diagnosed at approximately 19 months — longer than the population median first-line survival of approximately 10 to 18 months and consistent with possible immunotherapy benefit.

Case 2 — Pleural Mesothelioma With NF2 and TP53 Mutations

Case 2 was an 85-to-90-year-old male who presented with expressive aphasia. Brain imaging revealed a large hemorrhagic frontotemporal lesion, subsequently diagnosed as pleural mesothelioma metastatic to brain. He had no documented asbestos exposure. Tumor immunohistochemistry showed strong and diffuse staining of CK5/6, calretinin, and WT1, as well as patchy D2-40 expression, with absence of BerEP4, MOC-31, TTF-1, and Napsin-A — a phenotype consistent with mesothelial lineage and excluding lung adenocarcinoma. PD-L1 tumor proportion score was reported at 40%, characterized by the authors as low. ALK rearrangement and EGFR mutations were negative.

Next-generation sequencing identified two simultaneous somatic alterations: an NF2 splice-site mutation, c.1731_1737del+7, at variant allele fraction 23% (chr22:g.30077584), and a TP53 frameshift mutation, c.295_296del, at variant allele fraction 27% (chr17:g.7579391_7579392del). The authors characterize the TP53 frameshift as "unusual for MM," noting that the TP53 alteration spectrum in mesothelioma is more typically point mutations or subgenic deletions seen in only 14% of cases with probable biallelic inactivation per Chapel et al.

The patient was managed with stereotactic radiosurgery — 22 Gy in a single dose for the frontotemporal lesion (~15 mm maximum diameter, ~1.14 cm³) and 20 Gy in a single fraction for a subsequent right parietal lesion (~1.12 cm³), with a 16% volume reduction observed at three months on follow-up imaging. Systemic therapy was carboplatin at area-under-curve 3.5 mg/mL/min plus pemetrexed 400 mg/m² for three total cycles — both doses reduced from the standard adult regimen consistent with geriatric oncology dose-reduction practice. Extracranial progression involved liver, sternum, and spine (C3, T6) on positron emission tomography / computed tomography. Post-brain-metastasis survival was six months, characterized by the authors as relatively favorable for mesothelioma plus brain metastasis given that prior stereotactic radiosurgery case series have reported survival of one to seven months in this setting.

Authors' Stated Conclusions

The Harary group draws three principal conclusions from the two cases: (1) the TP53 frameshift mutation is unusual for mesothelioma and its potential association with rapid disease progression "warrants further investigation"; (2) "given the aggressive nature of MM, SRS may be preferable to WBRT due to its shorter treatment time and ease of combination with systemic regimens"; and (3) the absence of asbestos exposure in both cases plus the young age and family history of Case 1 support the value of systematic germline cancer-predisposition testing in young or asbestos-naive mesothelioma patients.

What Genetic Mutations Are Linked to Mesothelioma Brain Metastasis?

The genetic landscape of malignant pleural mesothelioma has been most rigorously characterized by Chapel and colleagues at Brigham and Women's Hospital, who published a hybrid-capture next-generation sequencing study of 84 pleural mesotheliomas (51 epithelioid, 27 biphasic, 6 sarcomatoid) with 57 reactive mesothelial proliferations as benign comparators in Modern Pathology in 2022. The four tumor-suppressor genes with complete coding and splicing coverage in their assay — BAP1, CDKN2A/MTAP, NF2, and TP53 — are the same four genes most directly implicated by Harary 2026 in mesothelioma with brain metastasis (with the addition of RAD51C in Case 1).

BAP1 (Chromosome 3p21.1)

BAP1 (BRCA1-associated protein 1) encodes a nuclear deubiquitinase. The first somatic BAP1 mutations in malignant pleural mesothelioma were reported by Bott et al. at Memorial Sloan-Kettering Cancer Center in Nature Genetics in 2011 — 23% of 53 tumors carried inactivating BAP1 mutations. Chapel et al. subsequently documented BAP1 alterations in 56% (47 of 84) of pleural mesotheliomas, with immunohistochemistry showing loss of BAP1 expression in 54% at 100% specificity versus reactive proliferations. Critically, BAP1 retention does not exclude mesothelioma — 44% of confirmed mesotheliomas retained BAP1 expression on immunohistochemistry, including Case 1 in the Harary 2026 series. Germline BAP1 carriers may also express nuclear BAP1 protein that appears intact by immunohistochemistry but is functionally dysfunctional, further limiting the negative predictive value of a single immunostain.

NF2 (Chromosome 22q12.2)

NF2 encodes merlin, a Hippo-pathway tumor suppressor. Pathogenic NF2 alterations occur in 68% (57 of 84) of pleural mesotheliomas per Chapel et al., with mechanisms including truncating mutations, splice-site mutations, deletions, and structural variants. Merlin immunohistochemistry (D1D8 antibody, Cell Signaling Technology) is 52% sensitive and 100% specific for mesothelioma versus reactive proliferations; adding Merlin to the BAP1 + MTAP immunopanel raises sensitivity from 79% to 90%, making the three-marker BAP1 + MTAP + Merlin panel the recommended standard. The NF2 splice-site mutation c.1731_1737del+7 identified in Harary Case 2 falls within the canonical splicing region and is mechanistically consistent with the loss-of-function alterations Chapel et al. describe.

CDKN2A and MTAP (Chromosome 9p21)

CDKN2A encodes the p16/INK4A cell cycle inhibitor. Homozygous CDKN2A deletion is the most common mechanism of inactivation (69% of pleural mesotheliomas per Chapel et al.), and MTAP — adjacent to CDKN2A on 9p21 — is co-deleted in all 48 MTAP-altered tumors in the Chapel cohort. MTAP immunohistochemistry (42-T antibody, Santa Cruz) is therefore a surrogate for CDKN2A homozygous deletion: 46% sensitive and 100% specific for mesothelioma, with significantly higher prevalence in non-epithelioid histology. MTAP immunohistochemistry was not reported in either Harary 2026 case — a notable gap given the 100% specificity of the assay.

TP53 (Chromosome 17p13.1)

TP53 alterations of any kind occur in 27% (23 of 84) of pleural mesotheliomas; restricted to point mutations or subgenic deletions with probable biallelic inactivation, the prevalence is 14% (12 of 84). Diffuse (mutant-pattern) p53 immunohistochemistry — defined as 2+ or 3+ staining in ≥80% of nuclei — is only 7% sensitive but 100% specific for TP53 mutation. Null-pattern p53 immunohistochemistry was NOT specific for malignancy in the Chapel cohort, so absent staining cannot be used to diagnose mesothelioma. Chapel et al. also documented that tumors with near-genome-wide loss of heterozygosity were enriched in TP53 point mutations (p=0.007), suggesting that TP53-mutated mesotheliomas may represent a genomically unstable, biologically distinct subset. The TP53 frameshift c.295_296del at variant allele fraction 27% identified in Harary Case 2 falls within this TP53-altered subset and underlies the authors' hypothesis of an association with rapid disease progression.

RAD51C (Chromosome 17q22)

RAD51C encodes a RAD51 paralog component of the homologous recombination (HR) DNA-repair complex. Germline RAD51C mutations are an established moderate-penetrance risk factor for breast and ovarian cancer; whether RAD51C variants predispose to mesothelioma is not yet established in the published literature. The RAD51C c.492 T>G (p.F164L) variant identified in Harary Case 1 is classified as a variant of uncertain significance with sparse gnomAD population entries; without paired germline testing, the somatic or hereditary origin cannot be determined. A relevant precedent comes from Schaefer et al. (2023, Modern Pathology), who reported a pathogenic BRCA1 germline mutation with somatic biallelic inactivation in one of three primary pericardial mesotheliomas — establishing that homologous-recombination germline mutations can drive pericardial mesothelioma and supporting systematic germline testing in young, asbestos-naive, or family-history-positive cases.

How Is a Brain Biopsy Diagnosed as Mesothelioma?

A brain biopsy from a patient with known or suspected mesothelioma requires a structured four-step immunohistochemistry workup to confirm the diagnosis, given the 17% rate of histologic dedifferentiation between primary and CNS sites documented by Miller et al. The sequence is:

1. Exclude glioma using glial markers — GFAP (glial fibrillary acidic protein), IDH1 (isocitrate dehydrogenase 1), ATRX, and H3 K27M
2. Exclude carcinoma using epithelial markers — TTF-1 and Napsin-A (lung adenocarcinoma), BerEP4 and MOC-31 (epithelial), claudin-4 (adenocarcinoma), carcinoembryonic antigen (CEA), and P40/p63 (squamous)
3. Confirm mesothelial origin using positive lineage markers — calretinin, cytokeratin 5/6 (CK5/6), Wilms tumor 1 (WT1), and D2-40 (podoplanin)
4. Confirm malignancy using tumor-suppressor immunohistochemistry — BAP1 (loss of nuclear expression), MTAP (loss of cytoplasmic expression as a surrogate for CDKN2A deletion), Merlin (loss; NF2 protein product), and p53 (diffuse mutant pattern)

In the Harary 2026 series, Case 1 expressed mesothelial lineage markers — WT1, CK5/6, D2-40, calretinin positive — with carcinoma markers (BerEP4, P40, claudin-4) negative, and BAP1 retained; Case 2 showed strong and diffuse CK5/6, calretinin, and WT1, patchy D2-40, with BerEP4, MOC-31, TTF-1, and Napsin-A all negative. The MTAP gap noted above means the malignancy-confirmation step in both Stanford cases was incomplete relative to the published standard.

For NGS confirmation, hybrid-capture panels with complete coverage of BAP1, CDKN2A/MTAP, NF2, and TP53 — for example the OncoPanel platform used by Chapel et al. — detect a pathogenic alteration in 95% of pleural mesotheliomas; in combination with immunohistochemistry, the yield reaches 99%. All somatic variants should be classified using the American College of Medical Genetics five-tier framework (pathogenic, likely pathogenic, variant of uncertain significance, likely benign, benign), with ClinVar and LOVD reviewed before clinical interpretation.

How Is Mesothelioma Brain Metastasis Treated?

Radiation therapy is the workhorse of local management for mesothelioma brain metastasis, with the choice between whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) driven by lesion number, lesion size, performance status, and overall systemic disease control.

Stereotactic Radiosurgery — RTOG 90-05 Dose-Size Framework

Single-fraction stereotactic radiosurgery dosing for brain metastases is anchored by RTOG protocol 90-05, the multicenter dose-escalation study published by Shaw and colleagues in the International Journal of Radiation Oncology, Biology, Physics in 2000. The trial enrolled 156 analyzable patients with recurrent previously irradiated primary brain tumors and brain metastases and established the following maximum tolerated doses for tumors up to 40 mm in maximum diameter:

• ≤20 mm: 24 Gy in a single fraction (limited by investigator reluctance to escalate further, not excess toxicity)
• 21–30 mm: 18 Gy in a single fraction
• 31–40 mm: 15 Gy in a single fraction

Tumors 21–40 mm in diameter were 7.3 to 16 times more likely to develop grade 3–5 neurotoxicity than tumors <20 mm. The actuarial radionecrosis incidence was 5%, 8%, 9%, and 11% at 6, 12, 18, and 24 months following radiosurgery, respectively. The 22 Gy and 20 Gy single-fraction doses used for the ~15 mm Case 2 lesions in Harary 2026 fall within the standard practice envelope established by RTOG 90-05 for small brain metastases.

Whole-Brain Radiotherapy and Hippocampal Avoidance

A 30 Gy in 10 fraction palliative WBRT regimen — 3 Gy per fraction — is widely used for patients with multiple brain metastases or with lesions too numerous or too large for SRS. The use of WBRT has been increasingly tempered by recognition of neurocognitive toxicity, particularly memory loss linked to hippocampal neural stem cell injury.

Brown and colleagues at the Mayo Clinic and a consortium of NRG Oncology centers conducted the definitive Phase III trial of hippocampal-avoidance WBRT (HA-WBRT) plus memantine versus standard WBRT plus memantine — NRG Oncology CC001, published in the Journal of Clinical Oncology in 2020. Between July 2015 and March 2018, 518 patients with brain metastases were randomized. At a median follow-up of 7.9 months for live patients, the risk of cognitive function failure was significantly lower with HA-WBRT plus memantine versus WBRT plus memantine — adjusted hazard ratio 0.74, 95% confidence interval 0.58 to 0.95, p=0.02. The difference was driven by less deterioration in executive function at four months (23.3% vs 40.4%; p=0.01) and learning and memory at six months. Treatment arms did not differ significantly in overall survival, intracranial progression-free survival, or toxicity. The trial concluded that HA-WBRT plus memantine "should be considered a standard of care for patients with good performance status who plan to receive WBRT for brain metastases with no metastases in the HA region." This Phase III evidence builds on the earlier Phase II single-arm trial RTOG 0933, published by Gondi and colleagues in 2014 in the Journal of Clinical Oncology, which first demonstrated memory preservation with hippocampal-avoidance WBRT compared with a historical control.

Case 1 in Harary 2026 received 30 Gy in 10 fractions for 14 brain lesions, with hippocampal avoidance applied to six of the ten fractions — a treatment approach consistent with NRG CC001 evidence for patients with no lesions in the hippocampal-avoidance region.

When SRS Is Preferred Over WBRT

The Harary 2026 authors explicitly recommend SRS over WBRT for mesothelioma brain metastasis in most circumstances, citing shorter treatment time, easier combination with systemic therapy, and accumulating evidence supporting SRS for up to 15 brain metastases. For lesions larger than 3 cm, fractionated SRS is generally preferred over single-fraction treatment to reduce radiation necrosis risk. The 22 Gy and 20 Gy regimens used in Harary Case 2 reflect this preference.

What Systemic Therapy Options Apply When Brain Metastasis Develops?

Systemic therapy for mesothelioma is determined by the primary disease site and histology, not by the presence of brain metastasis per se. For unresectable malignant pleural mesothelioma, the standard first-line regimen since October 2020 has been nivolumab plus ipilimumab, established by the Phase III CheckMate-743 trial published by Baas and colleagues in The Lancet in 2021. The trial randomized 605 patients to nivolumab 3 mg/kg every two weeks plus ipilimumab 1 mg/kg every six weeks for up to two years versus platinum (cisplatin or carboplatin) plus pemetrexed for up to six cycles. Median overall survival was 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy (hazard ratio 0.74, 96.6% confidence interval 0.60 to 0.91, p=0.0020); two-year overall survival was 41% versus 27%. Case 1 in Harary 2026 received nivolumab plus ipilimumab postoperatively despite having pericardial rather than pleural primary disease — an off-label use reflecting the absence of regulatory-approved regimens for pericardial mesothelioma.

For older or frailer patients, dose-reduced platinum-pemetrexed remains an alternative. Case 2 in Harary 2026 received carboplatin AUC 3.5 plus pemetrexed 400 mg/m² for three cycles — both doses reduced from the standard adult regimen (carboplatin AUC 5–6 and pemetrexed 500 mg/m²) consistent with geriatric oncology dose-reduction practice. PD-L1 tumor proportion score does not consistently predict immunotherapy benefit in mesothelioma; tumor mutational burden is generally low. Case 2's PD-L1 tumor proportion score of 40% characterized as "low" by the authors is consistent with the limited utility of this biomarker in mesothelioma decision-making.

What Is the Prognosis for Mesothelioma Brain Metastasis?

Survival after brain metastasis from mesothelioma is typically weeks to months. Miller et al. described brain metastasis as usually a late-stage end event, with rapid recurrence reported after surgery or stereotactic therapy in multiple case series. Prior to Harary 2026, fewer than 15 cases in the published literature documented post-brain-metastasis survival of six months or longer. Case 2 in Harary 2026 reached this six-month mark with stereotactic radiosurgery — characterized by the authors as relatively favorable in the context of the historical case series, and consistent with the broader SRS-versus-WBRT survival data in non-mesothelioma brain metastasis populations. Case 1 reached 21.25 months overall survival from initial mesothelioma diagnosis with brain metastasis diagnosed at approximately 19 months — substantially longer than the population median first-line survival of approximately 10 to 18 months and consistent with possible nivolumab-plus-ipilimumab benefit per CheckMate-743.

Mutation-prognosis relationships in mesothelioma are an emerging research area. Chapel et al. demonstrated that mesotheliomas with near-genome-wide loss of heterozygosity were enriched in TP53 point mutations (p=0.007), a finding consistent with a genomically unstable subtype carrying poor prognosis implications. The TP53 frameshift in Harary Case 2 falls within this genomically unstable category and supports the authors' hypothesis of an association with rapid progression. Larger cohort analyses are needed to determine whether TP53 biallelic inactivation, distinct from shallow chromosome 17p deletion, independently predicts central nervous system metastasis risk in malignant pleural mesothelioma.

What Knowledge Gaps Remain in Mesothelioma Brain Metastasis Research?

Harary 2026 raises at least five specific unanswered research questions:

1. What is the clonal relationship between primary mesothelioma and the brain metastasis? No paired primary plus brain-metastasis whole-exome or whole-genome sequencing has been published for mesothelioma. Acquired mutations enabling central nervous system seeding, dissemination routes, and whether brain-metastasis-specific somatic alterations exist are entirely unexplored.
2. Is the RAD51C c.492 T>G (p.F164L) variant in Case 1 somatic or germline, and what is its functional consequence? No germline sequencing was performed despite the patient's young age, pericardial primary, asbestos-naive status, and family history of early-onset cancer. Functional studies of p.F164L in mesothelial cell lines — assessing homologous-recombination capacity, RAD51C–RAD51D interaction, and platinum sensitivity — are needed. Future guidelines should mandate germline panel testing in all young-onset or asbestos-naive mesothelioma cases.
3. Does MTAP loss occur in mesothelioma brain metastases? MTAP immunohistochemistry was not reported in either Harary 2026 case, despite its 100% specificity for mesothelioma versus reactive proliferations. MTAP should be included in all future mesothelioma plus brain metastasis immunohistochemistry panels.
4. Can a dedicated mesothelioma brain metastasis prognostic scoring model be developed? No mesothelioma-specific brain-metastasis graded prognostic assessment (GPA) or equivalent system exists. A multicenter registry — potentially within the National Mesothelioma Virtual Bank framework — is needed to accumulate cases with matched genetic, immunohistochemical, treatment, and survival data.
5. Is TP53 frameshift a consistent predictor of central nervous system metastasis or rapid mesothelioma progression? Larger genomic cohort analyses are needed to determine whether TP53 biallelic inactivation independently predicts central nervous system metastasis risk in pleural mesothelioma.

Compensation, Trust Funds, and Legal Recourse for Mesothelioma Brain Metastasis

A mesothelioma diagnosis carrying brain metastasis remains compensable under U.S. asbestos law in the same way as mesothelioma confined to the thorax, peritoneum, or pericardium — the disease is mesothelioma regardless of whether it has spread to the central nervous system. Asbestos manufacturers that have filed for bankruptcy protection under Section 524(g) of the U.S. Bankruptcy Code maintain asbestos trust funds — currently holding approximately $30 billion in aggregate — to compensate exposure victims regardless of disease stage. Trust fund claims are not contingent on demonstrating that brain metastasis is causally linked to a specific defendant's asbestos product; the underlying mesothelioma diagnosis carries the claim.

Outside the trust fund framework, plaintiffs may pursue product liability or premises liability claims against living defendants and their insurers. The Harary 2026 cases highlight an additional clinical-legal consideration: both patients had no documented asbestos exposure, which complicates traditional occupational-exposure attribution. In young-onset, asbestos-naive, or family-history-positive mesothelioma cases, germline cancer-predisposition testing — for example BAP1, BRCA1, and the broader homologous-recombination panel — may be relevant both to clinical management and to litigation strategy. See the == External Links == section for legal-evaluation resources.

Related WikiMesothelioma Resources

• Mesothelioma_Diagnosis_and_Staging — the broader diagnostic workup, TNM staging system, and immunohistochemistry panels for mesothelioma at any anatomic site
• Mesothelioma_Biopsy_Procedures — tissue acquisition techniques and FFPE specimen handling for next-generation sequencing
• Pericardial_Mesothelioma — the rare primary site of Harary 2026 Case 1, with epidemiology and molecular landscape
• Mesothelioma_Molecular_and_Genetic_Testing — broader genetic and biomarker testing strategy in mesothelioma
• Mesothelioma_Blood_Tests_and_Biomarkers — serum mesothelin, fibulin-3, HMGB1, and other circulating markers
• Mesothelioma_Symptoms — including neurological presentations that should prompt brain imaging
• Asbestos_Trust_Funds — compensation pathways for mesothelioma patients and families
• Mesothelioma_Treatment_Costs_Quick_Reference — CheckMate-743 nivolumab + ipilimumab and systemic therapy cost context

Frequently Asked Questions

Can mesothelioma spread to the brain?

Yes, although it is uncommon. Pooled autopsy data from seven studies totaling 655 mesothelioma patients identified central nervous system metastases in 2.7% (18 patients), with individual study rates ranging from 0% to 3.8%. Clinical incidence on brain imaging is generally lower because most patients die of advanced thoracic or peritoneal disease before central nervous system spread becomes evident, and routine brain imaging is not part of standard mesothelioma staging or surveillance. New or progressive neurological symptoms in a mesothelioma patient should prompt contrast-enhanced brain magnetic resonance imaging.

How common is brain metastasis from mesothelioma?

Approximately 2.7% of mesothelioma patients develop central nervous system metastases by autopsy, based on the largest pooled analysis to date by Miller et al. (2014, Annals of the American Thoracic Society, PMID 25079105). Of 59 cases with histology specified, sarcomatoid mesothelioma was the most common subtype (31 of 59), followed by biphasic (14) and epithelioid (14). Notably, zero cases of primary peritoneal mesothelioma metastasizing to the central nervous system were identified across the pooled autopsy series of 655 patients or the 97 reviewed clinical cases — a striking organ-specific pattern.

What genetic mutations are found in mesothelioma brain metastasis?

The first dedicated genetic profiling of mesothelioma with brain metastasis was published by Harary et al. at Stanford University in May 2026 (Cancer Reports, PMID 42101078). Two cases were sequenced: Case 1 (pericardial primary) carried a RAD51C missense variant of uncertain significance (c.492 T>G, p.F164L); Case 2 (pleural primary) carried both an NF2 splice-site mutation (c.1731_1737del+7, variant allele fraction 23%) and a TP53 frameshift mutation (c.295_296del, variant allele fraction 27%). The TP53 frameshift is unusual for mesothelioma and the authors hypothesize a possible association with rapid disease progression.

Is surgery or radiation used for mesothelioma brain metastasis?

Radiation therapy is the primary local treatment. The choice depends on lesion number, size, performance status, and systemic disease control. Whole-brain radiotherapy at 30 Gy in 10 fractions is a standard palliative regimen, and hippocampal-avoidance whole-brain radiotherapy plus memantine significantly preserves cognitive function compared with standard whole-brain radiotherapy (adjusted hazard ratio 0.74; NRG Oncology CC001, Brown et al. 2020). Stereotactic radiosurgery is preferred for limited brain metastases, with maximum tolerated single-fraction doses of 24 Gy for tumors ≤20 mm, 18 Gy for 21–30 mm, and 15 Gy for 31–40 mm per RTOG 90-05 (Shaw et al. 2000). The Harary 2026 authors recommend stereotactic radiosurgery over whole-brain radiotherapy for mesothelioma brain metastasis in most circumstances, citing shorter treatment time and easier combination with systemic therapy.

What is NF2 mutation in mesothelioma?

NF2 (Neurofibromin 2) on chromosome 22q12.2 encodes merlin, a tumor suppressor in the Hippo signaling pathway. Pathogenic NF2 alterations — truncating mutations, splice-site mutations, deletions, and structural variants — occur in approximately 68% of pleural mesotheliomas, per Chapel et al. (2022, Modern Pathology, PMID 35459788). Merlin immunohistochemistry is 52% sensitive and 100% specific for mesothelioma, and adding Merlin to the BAP1 plus MTAP immunopanel raises diagnostic sensitivity from 79% to 90%. The NF2 splice-site mutation identified in Harary 2026 Case 2 is consistent with this loss-of-function spectrum.

External Links

• Harary PM et al. — Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis (Cancer Reports, 2026): PMID 42101078 — the anchor case series for this page, open access via PMC13154776.
• Miller AC et al. — Malignant Mesothelioma and Central Nervous System Metastases (Annals ATS, 2014): PMID 25079105 — the pooled autopsy analysis establishing 2.7% CNS prevalence.
• Chapel DB et al. — Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry (Modern Pathology, 2022): PMID 35459788 — the 84-tumor BAP1/MTAP/Merlin/p53 panel validation.
• Brown PD et al. — Hippocampal Avoidance During WBRT Plus Memantine, NRG Oncology CC001 (J Clin Oncol, 2020): PMID 32058845 — the Phase III cognitive-preservation trial.
• Shaw E et al. — Single-Dose Radiosurgical Treatment, RTOG 90-05 Final Report (IJROBP, 2000): PMID 10802351 — the maximum tolerated dose framework for single-fraction SRS.
• Danziger & De Llano — Free Mesothelioma Case Evaluation: legal assessment for mesothelioma patients and families, including those with brain metastasis or other late-stage spread.
• Danziger & De Llano — Mesothelioma Lawsuit Information: overview of asbestos litigation pathways including trust funds, settlements, and product liability claims.

Free Case Review for Mesothelioma With Brain Metastasis
Mesothelioma patients with brain metastasis — and their families — may qualify for compensation through the asbestos trust funds and product liability litigation, regardless of central nervous system spread.
Speak to a mesothelioma attorney	(855) 699-5441
Danziger & De Llano — Request a free case evaluation